Urology/Gynecology/G.I

The first segment is purely gynecological surgical devices, which deals exclusively with specific gynaecological procedures such as hysterectomy and its alternatives, hysterocopy and others including tubal patency screening, tubal ligation, dilation and curretage (D&C) and myometomy. Thus this segment analyzes markets for endoscopes, fluid management systems, hysteroscopy systems, generation II devices, and other gynecological surgery device markets such as curettage systems, trocars and tubal occlusion systems.

The second segment deals with urological treatments such as those for stress urinary incontinence (SUI), uterine fibroids, and abnormal uterine bleeding (AUB). Thus the products analyzed in this segment are sling systems, suspension devices, stents and meshes for drug coatings. Market opportunity is immense due to the presence of a large untapped patient population and changing trends in surgical techniques.

The potential for this market is mainly due to the enormous increase in burden of uterine pathologies in the last three to four years. The Compound Annual Growth Rate (CAGR) for minimally invasive procedures is consistent at 15-20 percent and this is expected to drive the market and create enormous opportunities for participants.

In terms of size, growth, and opportunities in any health care market, products made exclusively for female patients heavily outnumber those for males. In the United States too, 54 percent of the population comprises women. Furthermore, they contribute to two-third of all health care visits in the United States. In 2003, these were more than 500 million, and were expected to increase with a CAGR of over 14 percent.

 

According to a recent article published by the Centers for Disease Control and Prevention (CDC), women account for around 64 percent of all doctor appointments and 59 percent of the purchase of prescribed drug and gender-specific products